RVTY vs SYRE
Revvity vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
72
Buy
| Metric | RVTY | SYRE |
|---|
| AI Score |
75
|
72
|
| Price |
$116.77
|
$103.56
|
| P/E Ratio |
55.64×
|
-53.14×
|
| ROE |
3.3%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
52.1%
|
0.0%
|
| Debt / Equity |
0.46×
|
0.00×
|
| Dividend Yield |
0.2%
|
0.0%
|
| RSI (14) |
65.1
|
54.6
|
| Beta |
1.072
|
3.026
|
| Expected Upside |
+1.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for RVTY versus SYRE.
RVTY leads by 3 points.
RVTY scores 75/100 (Buy) versus SYRE at 72/100 (Buy).
RVTY Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 2971.31). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Stochastic RSI (92.1) confirms overbought conditions.
- Risk/reward is unfavorable: 28.5% downside vs 1.3% upside.
SYRE Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical